Your browser is no longer supported. Please, upgrade your browser.
argenx SE
Index- P/E- EPS (ttm)-14.04 Insider Own- Shs Outstand51.31M Perf Week-3.93%
Market Cap13.25B Forward P/E- EPS next Y-15.58 Insider Trans- Shs Float49.53M Perf Month-4.00%
Income- PEG- EPS next Q-3.16 Inst Own50.76% Short Float1.74% Perf Quarter-29.86%
Sales54.53M P/S242.92 EPS this Y-21.20% Inst Trans- Short Ratio4.99 Perf Half Y0.79%
Book/sh28.68 P/B9.00 EPS next Y8.50% ROA- Target Price336.00 Perf Year69.80%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range141.26 - 382.15 Perf YTD-12.20%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-31.35% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low85.71% ATR9.03
Employees336 Current Ratio- Sales Q/Q-44.20% Oper. Margin- RSI (14)39.14 Volatility3.45% 2.96%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.02 Prev Close258.21
ShortableYes LT Debt/Eq- EarningsMar 04 BMO Payout- Avg Volume172.87K Price262.34
Recom2.10 SMA20-5.63% SMA50-8.48% SMA200-5.93% Volume43,571 Change1.60%
May-10-21Upgrade H.C. Wainwright Neutral → Buy $320 → $400
Apr-23-21Initiated Redburn Neutral
Mar-05-21Reiterated H.C. Wainwright Neutral $265 → $320
Feb-02-21Downgrade Piper Sandler Overweight → Neutral $303
Jan-04-21Downgrade Guggenheim Buy → Neutral
Aug-25-20Initiated Raymond James Outperform $257
Aug-19-20Downgrade Evercore ISI Outperform → In-line
Jul-29-20Initiated H.C. Wainwright Neutral $272
Feb-10-20Initiated BofA/Merrill Buy
Nov-05-19Initiated Credit Suisse Neutral $137
Oct-31-19Upgrade William Blair Mkt Perform → Outperform
Oct-22-19Initiated JP Morgan Overweight $167
Sep-27-19Initiated Wells Fargo Market Perform
Sep-16-19Resumed Cowen Outperform
Jun-28-19Initiated Robert W. Baird Outperform
Jan-18-19Resumed SunTrust Buy
Jan-04-19Initiated Morgan Stanley Overweight
Dec-17-18Initiated Goldman Buy
Dec-14-18Initiated Wolfe Research Outperform
Jun-29-18Initiated Nomura Buy $161
May-11-21 05:00AM  
May-10-21 11:30PM  
May-07-21 01:00AM  
Apr-28-21 01:00AM  
Mar-30-21 04:00PM  
Mar-04-21 12:30PM  
Mar-02-21 02:00AM  
Feb-25-21 01:00AM  
Feb-05-21 04:01PM  
Feb-04-21 01:00AM  
Feb-02-21 10:15PM  
Feb-01-21 04:01PM  
Jan-08-21 01:00AM  
Jan-07-21 08:20AM  
Jan-06-21 04:01PM  
Jan-04-21 01:00AM  
Dec-19-20 09:32PM  
Dec-14-20 10:12AM  
Nov-23-20 01:00AM  
Nov-17-20 07:00AM  
Nov-09-20 01:00AM  
Nov-03-20 04:14PM  
Oct-22-20 12:30PM  
Oct-15-20 01:00AM  
Oct-06-20 08:24AM  
Oct-05-20 01:00AM  
Sep-16-20 04:53PM  
Sep-02-20 01:00AM  
Aug-04-20 01:00AM  
Jul-30-20 01:00AM  
Jul-29-20 01:46PM  
Jul-20-20 12:15PM  
Jul-01-20 09:24AM  
Jun-15-20 11:09AM  
Jun-01-20 04:00PM  
May-29-20 01:00AM  
May-28-20 12:15AM  
May-27-20 10:08AM  
May-26-20 04:01PM  
May-14-20 03:30PM  
May-12-20 09:52AM  
May-11-20 05:22AM  
May-08-20 11:46AM  
Mar-22-20 10:18PM  
Feb-27-20 08:09AM  
Feb-26-20 08:57AM  
Feb-09-20 03:01AM  
Jan-07-20 08:40AM  
Dec-29-19 09:40PM  
Dec-07-19 08:02AM  
Nov-22-19 03:22PM  
Nov-12-19 04:00PM  
Nov-10-19 02:52AM  
Nov-08-19 01:00AM  
Nov-06-19 10:45PM  
Oct-24-19 01:00AM  
Oct-14-19 10:14PM  
Sep-25-19 03:34AM  
Sep-03-19 01:00AM  
Aug-07-19 04:43AM  
Aug-06-19 01:00AM  
Aug-01-19 01:00AM  
Jul-25-19 01:00AM  
Jul-08-19 10:00AM  
Jun-20-19 01:35PM  
Jun-05-19 08:37AM  
May-22-19 07:34AM  
May-02-19 06:43PM  
Apr-25-19 02:38PM  
Apr-13-19 07:41AM  
Apr-03-19 05:35AM  
Feb-28-19 07:00AM  
Feb-04-19 01:00AM  
Jan-23-19 07:55AM  
Jan-22-19 01:52AM  
Dec-26-18 02:22PM  
Dec-03-18 04:09AM  
Nov-01-18 09:15AM  
Oct-25-18 02:04AM  
Oct-09-18 01:00AM  
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.A.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.